Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of cilostazol in preventing
recurrence of cerebral infarction and the safety of long-term administration of the drug (100
mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral
embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg,
once daily).